A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings.
HIV
HPTN
HPTN 071
Illumina
NGS
PopART
RNA virus
SMARTer
antiretroviral resistance
antiretroviral therapy
bait capture
drug resistance
drug resistance evolution
gene sequencing
human immunodeficiency virus
phylogenetic analysis
phylogenetics
public health
short-read sequencing
sub-Saharan Africa
surveillance studies
viral evolution
viral genomics
viral sequencing
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
22 09 2020
22 09 2020
Historique:
received:
02
03
2020
accepted:
10
07
2020
pubmed:
17
7
2020
medline:
24
6
2021
entrez:
17
7
2020
Statut:
epublish
Résumé
Viral genetic sequencing can be used to monitor the spread of HIV drug resistance, identify appropriate antiretroviral regimes, and characterize transmission dynamics. Despite decreasing costs, next-generation sequencing (NGS) is still prohibitively costly for routine use in generalized HIV epidemics in low- and middle-income countries. Here, we present veSEQ-HIV, a high-throughput, cost-effective NGS sequencing method and computational pipeline tailored specifically to HIV, which can be performed using leftover blood drawn for routine CD4 cell count testing. This method overcomes several major technical challenges that have prevented HIV sequencing from being used routinely in public health efforts; it is fast, robust, and cost-efficient, and generates full genomic sequences of diverse strains of HIV without bias. The complete veSEQ-HIV pipeline provides viral load estimates and quantitative summaries of drug resistance mutations; it also exploits information on within-host viral diversity to construct directed transmission networks. We evaluated the method's performance using 1,620 plasma samples collected from individuals attending 10 large urban clinics in Zambia as part of the HPTN 071-2 study (PopART Phylogenetics). Whole HIV genomes were recovered from 91% of samples with a viral load of >1,000 copies/ml. The cost of the assay (30 GBP per sample) compares favorably with existing VL and HIV genotyping tests, proving an affordable option for combining HIV clinical monitoring with molecular epidemiology and drug resistance surveillance in low-income settings.
Identifiants
pubmed: 32669382
pii: JCM.00382-20
doi: 10.1128/JCM.00382-20
pmc: PMC7512176
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : PEPFAR
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068613
Pays : United States
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Informations de copyright
Copyright © 2020 Bonsall et al.
Références
PLoS Pathog. 2017 Jan 9;13(1):e1006000
pubmed: 28068413
Lancet. 2012 Oct 6;380(9849):1250-8
pubmed: 22828485
Front Microbiol. 2018 Sep 13;9:2150
pubmed: 30271393
AIDS. 2017 Nov 13;31(17):2427-2429
pubmed: 28926401
J Mol Diagn. 2019 Nov;21(6):961-970
pubmed: 31382033
Trials. 2014 Feb 13;15:57
pubmed: 24524229
Genome Res. 2017 May;27(5):824-834
pubmed: 28298430
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
F1000Res. 2015 Oct 13;4:1062
pubmed: 27092241
Infect Genet Evol. 2013 Oct;19:337-48
pubmed: 23660484
BMC Biotechnol. 2013 Nov 20;13:104
pubmed: 24256843
Bioinformatics. 2012 Dec 1;28(23):3150-2
pubmed: 23060610
AIDS Res Hum Retroviruses. 2017 May 25;33(11):1083-1098
pubmed: 28540766
J Clin Microbiol. 2012 Dec;50(12):3838-44
pubmed: 22993180
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
PLoS Biol. 2017 Jun 12;15(6):e2001855
pubmed: 28604782
J Antimicrob Chemother. 2020 Dec 1;75(12):3510-3516
pubmed: 32772080
J Clin Microbiol. 2016 Oct;54(10):2470-84
pubmed: 27385709
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Nat Med. 2000 Nov;6(11):1290-2
pubmed: 11062545
Mol Biol Evol. 2018 Mar 1;35(3):719-733
pubmed: 29186559
Lancet HIV. 2018 Nov;5(11):e656-e666
pubmed: 30174214
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):181-95
pubmed: 24977473
Genome Biol. 2014 Mar 03;15(3):R46
pubmed: 24580807
J Clin Microbiol. 2014 Feb;52(2):517-23
pubmed: 24478482
J Virol. 2015 Aug;89(16):8540-55
pubmed: 26041299
J Int AIDS Soc. 2018 Oct;21(10):e25193
pubmed: 30350345
Biotechniques. 2001 Apr;30(4):892-7
pubmed: 11314272
Virus Evol. 2018 May 18;4(1):vey007
pubmed: 29876136